SME Times is powered by   
Search News
Just in:   • Indian equity indices end slightly lower ahead of RBI's MPC outcome  • J&K’s Kishtwar selected as aspirational agricultural district under PMDDKY  • Indian stock market opens higher as RBI MPC begins  • Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw  • Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns 
Last updated: 27 Sep, 2014  

BiOZEEN appoints Mahadevan as President and CEO

PR Newswire | 28 Feb, 2012
BiOZEEN appoints Mahadevan as President & Chief Executive Officer

MUMBAI, India: Industry leader and former Merck Millipore Executive tapped as the President & CEO of the only company in the Industry Integrating equipment manufacturing, consultancy and training under one roof

BiOZEEN (http://www.biozeen.com), a niche bioprocess engineering organization delivering end-to-end solutions to the biopharmaceutical sector across the globe, today announced the appointment of Mr. Mahadevan as the President & Chief Executive Officer (CEO).

Photo: http://www.apo-mail.org/BiOZEEN.JPG (Mr. Mahadevan the newly appointed President & Chief Executive Officer, BiOZEEN)

Logo: http://www.apo-mail.org/biozeen.jpg

Mahadevan most recently served as the Global Director and Commercial leader with Merck Millipore where he led global market segment strategic initiatives. He brings to board over twenty four years of strong understanding of Healthcare and Life Sciences sector.

Dr. Anil Paul Kariath speaking on behalf of the Board of Directors, BiOZEEN expressed his delight on having the versatile leader by stating, “BiOZEEN identified in Mahadevan a dynamic leader with clarity on visionary and operational skills, both from technology and geography perspective, making him the right match for us.” He further added that, “In the past Mr. Mahadevan has executed global strategies with his industry knowledge, strong networking skills and industrial contacts. I believe this will help him steer Biozeen to the next level.”

Mahadevan cites several opportunities for the industry and organization, “Life Sciences and emerging markets is where the next wave of biotech growth is poised to occur. As a total solutions provider our business model integrates Consulting, Design & Build Equipments and training that would insure productivity and facilitate growth in the bio-pharmaceutical industry as we at BiOZEEN plan to be their unique partner.”

Distributed by the African Press Organization on behalf of BiOZEEN.

About BiOZEEN:

Started operations in the year 2006, BiOZEEN (http://www.biozeen.com) is a turnkey bioprocess engineering organization delivering end-to-end solutions to the biopharmaceutical sector across the globe. Operational through a state-of-the-art facility sprawling over an area of eight acres in Bangalore, BiOZEEN undertakes Bioprocess Equipment Manufacturing, Consultancy Services, Manpower Training and Bioprocess Research. With a headcount of over 150 people, BiOZEEN comprises of a team of professionals from various disciplines such as bioprocess engineers, microbiologists, technicians, chemists and scientists with diverse experience from the Biologics and Biopharmaceutical industry. With customers in more than 10 countries around the world, BiOZEEN enables productivity at institutions and corporations that shape global health. Global Customers include LG Life Sciences, Binex South Korea, The Biovac Institute South Africa, DAPH Srilanka and some of the Indian customers include Serum Institute, Shantha Biotech, Biological E, and Reliance Life Sciences. BiOZEEN is certified for compliance to ISO 9001:2008.

For further details you can visit the link- www.biozeen.com

For Further Information Contact:

Salma Khan

Gutenberg Communications

Salma@gutenbergpr.com

 

 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter